Navigation Links
AAHIVM Encouraged by TMC125 Approval
Date:2/4/2008

New HIV Medication Could Offer More Options for Treatment-Experienced

Patients

WASHINGTON, Feb. 4 /PRNewswire/ -- The American Academy of HIV Medicine (AAHIVM), a national organization of HIV-treating physicians, nurse practitioners and physician assistants, praised the accelerated U.S. Food and Drug Administration (FDA) approval of the anti-HIV medication TMC125 (etravirine), the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be introduced in nearly 10 years, and the first to show antiviral activity in treatment-experienced adult patients with NNRTI-resistant virus. NNRTI drug resistance occurs when HIV develops mutations that partially or completely stop the NNRTI from binding to the reverse transcriptase enzyme, causing the drug to lose effectiveness.

"With the FDA's accelerated approval of TMC125, we are encouraged by the increased treatment options that are now available for our patients," said AAHIVM Board Chair Jeffrey Schouten, MD, AAHIVS. "With antiretroviral therapy now in its third decade, HIV care providers have increasing concern over the cross-resistance of the NNRTI class. A patient resistant to one NNRTI is generally resistant to the other NNRTIs available, which significantly limits our options with our longtime and treatment-experienced patients. This drug may also be very useful for people who are infected with an NNRTI-resistant strain of HIV which is not uncommon. TMC125 offers HIV care providers another treatment option that could dramatically increase the capacity for continued success in their patients' long-term HIV care."

FDA-accelerated approval procedures allow for earlier approval of drugs that provide a meaningful therapeutic advantage over existing treatment for serious or life-threatening diseases. Longer-term data will be required before the FDA can consider traditional approval of TMC125. Dr. Schouten emphasized the importance of closely monitoring changes to any treatment regimen to recognize possible barriers to treatment adherence and to maximize potential for treatment success.

The American Academy of HIV Medicine is an independent organization of AAHIVM HIV Specialists(TM) and other health care professionals dedicated to advancing excellence in HIV/AIDS care. Through advocacy and education, AAHIVM is committed to supporting HIV clinicians and to ensuring better care for those living with HIV disease. AAHIVM is the only U.S. medical organization serving a membership of MDs, DOs, NPs and PAs, and providing all members the opportunity to credential as HIV Specialists(TM).


'/>"/>
SOURCE The AIDS Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Families Encouraged to Enjoy Healthy Kids Fest January 12 at the Blue Cross RiverRink
2. Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking
3. New York City Cancer Patients, Survivors and Care Givers Encouraged to Keep Going(R)
4. Radiologists encouraged to look beyond cancer for clinically unseen diseases
5. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
6. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
7. Researchers query FDA about updating requirements for drug approval
8. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
9. ATS Medical Provides Update on First Generation Tissue Valve Approval
10. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
11. China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Secure Exchange Solutions, the leading ... of hospitals, health information exchanges, physicians and patients, announced today that SES Direct ... Edition Health IT Module Certification via Drummond Group LLC, an Authorized Certification Body ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leads to fewer trips the emergency room, fewer hospital admissions, and better blood ... of Managed Care® (AJMC®) finds. The study can be found here . ...
(Date:2/22/2017)... Fla. (PRWEB) , ... February 22, 2017 , ... ... is just as effective on smaller and sometimes harder to reach ones, according ... were presented at the International Stroke Conference in Houston by Ricardo A. Hanel, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery management ... on the App Store and Google Play . Florida-based Sober Network, ... and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management app ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 According to a new market ... SIMS, CUSCO), Application (Laparoscopy, Colposcopy, Hysteroscopy, D&C, Ablation, Biopsy), & End ... published by MarketsandMarkets, the global market is expected to reach USD ... a CAGR of 7.1% during the forecast period. ... ...
(Date:2/22/2017)... PORTLAND, Oregon and PUNE, India ... report published by Allied Market Research, titled, "Automated Radio Synthesis ... that the world automated radiosynthesis modules market was worth $20 ... 2022, growing at a CAGR of 6.6% from 2016 to ... largest share in terms of both market revenues and unit ...
(Date:2/22/2017)... Conn. , Feb. 22, 2017   Protein ... maker of Flublok® Influenza Vaccine , announced today ... Partnership for Influenza Vaccine Introduction (PIVI) and the Mongolian ... devastating impacts of the flu.  The doses of Flublok ... Mongolia for health care workers, ...
Breaking Medicine Technology: